In a notable legal development, Seattle-based NanoString Technologies Inc. has been found to have willfully infringed several gene technology patents exclusively licensed to 10x Genomics, a leading biotechnology company. The verdict came from a Delaware federal jury on November 17th, 2023.
As a result of the patent infringement, NanoString has been ordered to pay a considerable sum in damages. The total amount awarded to 10x Genomics exceeds $31 million. This substantial compensation is indicative of the scale of the patent conflict between these two major players in the biotech industry.
NanoString, a prominent provider of life science tools for translational research and molecular diagnostics, is now in a challenging position. The company has been found to have unlawfully used gene technology patents that were exclusively licensed to 10x Genomics, thereby breaching patent laws which protect the intellectual property rights of innovators.
In contrast, this legal victory is a significant boost for 10x Genomics. The company’s exclusive licenses in gene technology have been acknowledged and protected – an outcome that reinforces the value of patent rights within the biotech industry.
For more detailed insights into this case, you can read the original article on Law360.